Cost-Effectiveness of Tranexamic Acid for Trauma Patients
Author Information
Author(s): Carla Guerriero, John Cairns, Pablo Perel, Haleema Shakur, Ian Roberts
Primary Institution: London School of Hygiene and Tropical Medicine
Hypothesis
Is administering tranexamic acid (TXA) to bleeding trauma patients cost-effective in different income settings?
Conclusion
Early administration of TXA to bleeding trauma patients is likely to be highly cost effective in low, middle, and high income settings.
Supporting Evidence
- TXA administration saved an estimated 372, 315, and 755 life years per 1,000 trauma patients in Tanzania, India, and the UK respectively.
- The incremental cost per life year gained was $48, $66, and $64 in Tanzania, India, and the UK respectively.
- The study used data from the CRASH-2 trial, which showed TXA reduces the risk of death in bleeding trauma patients.
Takeaway
Giving a medicine called TXA to people who are hurt and bleeding can help save lives and is not too expensive, no matter where you are in the world.
Methodology
A Markov model was used to assess the cost effectiveness of TXA in Tanzania, India, and the UK, measuring life years gained and costs associated with TXA administration.
Potential Biases
Potential underestimation of future health service savings due to not accounting for long-term health benefits of TXA.
Limitations
The study relies on modeling survival over 12 months using data for the first 28 days, which may not fully capture long-term outcomes.
Participant Demographics
The study evaluated trauma patients in low, middle, and high income countries.
Statistical Information
P-Value
0.0095
Confidence Interval
95% CI 0.81 to 0.95
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website